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regulatory requirements on efﬁ cacy and safety. Target product proﬁ les (TPPs) are 
developed to evaluate critical assumptions underlying these parameters. Subsequently, 
hedonic market research tools (e.g., conjoint analysis) may be used to evaluate infor-
mally pricing/reimbursement potential based on the TPP. We explore a more direct 
approach: applying a minimal cost-effectiveness threshold used by health technology 
assessment agencies (such as the UK’s NICE) to derive formally a minimally acceptable
clinical TPP vector and a maximally acceptable value-based price. METHODS: A
generalizable, hypothetical data-based, Markov decision model was developed to 
compare experimental treatment, A, to existing standard treatment, B, in a chronic 
disease. Three sets of clinical parameters were assigned: treatment A was assumed to
offer better efﬁ cacy, a worse AE proﬁ le, and a higher risk of relapse (presumably due 
to its lesser suitability in maintenance treatment) than treatment B. Plausible quality-
adjusted life years (QALYs) and medical costs were assigned based on time in each of 
the health states of remission, progressive disease/relapse, and death. RESULTS: Using
Markov cohort analysis, at a base case TPP, one-way sensitivity analysis yielded the 
maximum justiﬁ able value-based price premium for A vs. B. For a hypothetical A vs. 
B price premium, multi-way sensitivity generated minimally acceptable TPP vectors
for A that met the reimbursement threshold. A tornado diagram analysis yielded key 
uncertainty drivers. Using Markov micro-simulation, we generated expected net mon-
etary beneﬁ t (NMB) acceptability curves for A vs. B, varying the key drivers. For TPPs
that yielded convergent NMBs across treatments, the expected value of acquiring 
additional information (VOI) with a clinical trial was generated. CONCLUSIONS:
TPPs that are explicitly derived from required cost-effectiveness thresholds should be 
used to guide drug development and to help determine price expectations.
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OBJECTIVES: The objective was to examine the association between nonadherence 
to oral hypoglycemic agents and subsequent all-cause hospitalization, emergency room 
(ER) visit, and mortality among Medicare Part D enrollees with diabetes. METHODS:
This is a longitudinal retrospective cohort study. The study sample consisted of Medi-
care Part D enrollees with diabetes from six states (Alabama, California, Florida, 
Mississippi, New York, and Ohio) who had ﬁ lled at least one prescription for oral 
hypoglycemic agents during the ﬁ rst 6 months of 2006. Adherence was measured using 
proportion of days covered (PDC). Subjects were classiﬁ ed as adherent (PDC q 0.8),
poor adherent (0.5 a PDC  0.8), and very poor adherent (0  PDC  0.5). Medicare
Part A records and beneﬁ ciary ﬁ les from July 1, 2006 to March 31, 2007 were evalu-
ated for all-cause hospital admissions, ER visits, and mortality. Multivariate regression 
analyses were performed to assess the independent association between medication
adherence and outcomes. RESULTS: Data were available for 1,101,533 patients. 
Among them, 58.4% were females and the mean age was 71.7 years. About 64.9% 
were adherent, 11.2% were poor-adherent, and 24.0% were very poor-adherent
with oral hypoglycemics. After controlling for age, gender, race, and comorbidities 
(Charlson comorbidity index), in comparison to adherent patients, the odds for all-
cause hospital admission, ER visit, and mortality were 17.9% (OR: 1.179; 95%CI: 
1.156–1.204), 6.3% (OR: 1.063; 95%CI: 1.048–1.077), and 7.1% (OR: 1.071; 
95%CI: 1.037–1.106) higher for poor-adherent patients. Compared to adherent 
patients, those with very poor adherence were 22.9% (OR: 1.229; 95%CI: 1.211–
1.247), 17.1% (OR: 1.171; 95%CI: 1.160–1.183), and 10.4% (OR: 1.104; 95%CI:
1.079–1.129) more likely to be hospitalized, have visited ER, or die during outcome 
measurement period. CONCLUSIONS: The results suggest that nonadherence to oral 
hypoglycemic agents is relatively common and appears to be associated with adverse 
clinical outcomes. Medicare prescription drug plans should consider developing tar-
geted interventions to improve adherence to oral hypoglycemic agents.
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OBJECTIVES: Although racial disparities in the prevalence and associated costs of 
Alzheimer’s disease and related dementias (ADRD) have been documented in the 
elderly, no data examine whether these differences translate into differences in drug 
treatment. The objective of this study was to investigate racial disparities in the drug
therapy for ADRD and its usual manifestations, depression and psychiatric disorders.
METHODS: Community-dwelling elderly Medicare beneﬁ ciaries with ADRD were
identiﬁ ed from the 2000–2004 Medicare Current Beneﬁ ciary Survey Cost and Use ﬁ les 
linked with Medicare claims (n  2,865). Generalized estimating equations were 
employed to calculate prevalence ratios (PRs) for use of anti-dementia medications, 
anti-depressants, and anti-psychotics by race, controlling for demographic character-
istics, functional status, prescription drug insurance, and comorbidities. RESULTS:
The prevalence of ADRD was signiﬁ cantly higher in minority beneﬁ ciaries than in 
non-minority beneﬁ ciaries (8.1% vs. 5.7%, p  0.001), whereas anti-dementia medica-
tion use was 28% lower among minorities (PR  0.72, 95% conﬁ dence interval [CI]
 0.58, 0.88). Depression was common in both groups (68.4% in minorities vs. 70.8% 
in non-minorities, p  0.332), but minority beneﬁ ciaries were 40% less likely to receive 
anti-depressant therapy (PR  0.60, 95% CI  0.42, 0.85). No racial differences were
observed in prevalence of psychiatric disorders (17.6% vs. 20.8%, p  0.096) or anti-
psychotic drug use (PR  1.06, 95% CI  0.78, 1.44). CONCLUSIONS: Although 
minority Medicare beneﬁ ciaries were more likely to suffer from ADRD, they were
signiﬁ cantly less likely to receive drug therapy for the condition and the coexisting 
depression. Under-use of appropriate drug therapy may lead to expensive inpatient
hospitalization and nursing home care, resulting in poorer heath outcomes and sub-
stantial burden on the health care system. The identiﬁ cation of clinically-modiﬁ able
factors associated with under-treatment is critical to improve health outcomes and 
reduce cost.
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OBJECTIVES: To describe utilization patterns of lipid lowering drugs (LLD) and to
examine the relationship between LLD use and all-cause hospitalizations, emergency 
room visits and mortality among Medicare patients with diabetes. METHODS: This 
is a longitudinal retrospective cohort study. The study sample consisted of diabetic 
Medicare Part D beneﬁ ciaries from six states, including Alabama, California, Florida, 
Mississippi, New York and Ohio. Beneﬁ ciaries was identiﬁ ed as diabetic using a 
combination of ICD9 code for diabetes (‘250.xx’) and NDC codes for insulin or oral 
hypoglycemic agents. Utilization of LLDs in Medicare Part D records during the ﬁ rst 
6 months of 2006 was evaluated and the measure was dichotomized as not using and 
using LLD. The primary outcomes of interest were all-cause hospitalization, all-cause 
emergency room (ER) visits and all-cause mortality. Multivariable regression analysis
was performed to assess the association between LLD utilization and outcomes.
RESULTS: The study sample constituted of 1,888,682 Part D enrollees with diabetes.
Fifty-one percent of them were users of LLD. Of the users, 59% were female, 84% 
were over 65 years of age and 67% were white. In unadjusted analysis, patients who 
used LLD had lower all-cause hospitalizations (OR: 0.761, 95% CI 0.754–0.767),
lower ER visits (OR: 0.909, 95% CI 0.903–0.914) and lower all-cause mortality (OR: 
0.567 95% CI 0.559–0.574). When adjusted for age, gender, race and comorbidities
in multivariable analysis, LLD utilization remained signiﬁ cantly associated with lower 
risks for all-cause hospitalizations (OR: 0.862, 95% CI 0.854–0.869), lower ER visits 
(OR: 0.801, 95% CI 0.796–0.806) and lower all-cause mortality (OR: 0.646, 95% 
CI 0.637–0.655). CONCLUSIONS: In conclusion, approximately 50% of the patients
with diabetes received LLDs in the study period and utilization of LLDs are shown
to be associated with improved outcomes in patients with diabetes after controlling
for patient demographics and comorbidities.
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OBJECTIVES: The purpose of the study was to examine the impact of Medicare new
drug beneﬁ t (Part D) on the utilization of inappropriate psychotropic medications 
(IPM) in the elderly. METHODS: The effect of Part D was measured using 24 months
(2005–2006) pharmacy claims data provided by one of the largest retail pharmacy
chains in the United States. Among the approximately 70 million individuals who 
ﬁ lled prescriptions at the pharmacy chain in 2006, 11% were 65 years or older. IPM 
was deﬁ ned based on Beer’s Criteria. Segmented regression of interrupted time series 
analysis was applied to evaluate changes in the monthly prevalence of IPM that were
excluded and included in the Part D formulary in the elderly population 65 years or
older. RESULTS: Among the 2.52 million elderly who ﬁ lled psychotropic medications
in the retail pharmacy chain in 2005, 0.72 million (28.5%) ﬁ lled at least one IPM. 
The implementation of Part D caused a sudden [1.21% (P  0.0001)] and a sustained
drop [0.05% per month (P  0.037)] in the prevalence of IPM. The seniors who 
enrolled in Part D were affected more than those who did not. Of 0.74 million seniors 
who ﬁ lled IPM in 2006, only 12.81% were Part D enrollees. The reduction in IPM 
utilization was mainly due to the decrease in use of those medications excluded from 
the Part D formulary. The number of benzodiazepine and barbiturate prescriptions
(medications excluded from Part D formulary) dispensed in 2006 dropped 6.16% 
compared to 2005. There is no statistically signiﬁ cant change in the use of IPM
(antidepressants and antipsychotics) that were included in the Part D formulary. 
CONCLUSIONS: The implementation of Medicare Part D resulted in a decrease of 
IPM and thereby improving the quality of care in the elderly. Further study is war-
ranted to assess the long term effect of Part D on IPM.
